Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 151 Oyster Point Blvd., Suite 400 SOUTH SAN FRANCISCO CA 94080 |
Tel: | N/A |
Website: | https://cytomx.com |
IR: | See website |
Key People | ||
Sean A. Mccarthy Chairman of the Board, Chief Executive Officer | Marcia P. Belvin Senior Vice President, Chief Scientific Officer | Lloyd A. Rowland Senior Vice President, Chief Compliance Officer, General Counsel, Secretary | Jeffrey Landau Senior Vice President, Chief Business Officer and Head of Strategy |
Business Overview |
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers. |
Financial Overview |
For the fiscal year ended 31 December 2023, CytomX Therapeutics Inc revenues increased 90% to $101.2M. Net loss decreased 99% to $569K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development decrease of 26% to $74.8M (expense), General and administrative decrease of 26% to $24.4M (expense). |
Employees: | 120 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $130.28M as of Dec 31, 2023 |
Annual revenue (TTM): | $101.21M as of Dec 31, 2023 |
EBITDA (TTM): | -$4.31M as of Dec 31, 2023 |
Net annual income (TTM): | -$0.57M as of Dec 31, 2023 |
Free cash flow (TTM): | -$56.88M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 67,731,764 as of Mar 19, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |